Roflumilast N-oxide

Roflumilast N-oxide is a PDE type 4 inhibitor.

Product Specifications

CAS Number

[292135-78-5]

UNSPSC

12352005

Hazard Statement

H302, H315, H320, H335

Target

Drug Metabolite; Phosphodiesterase (PDE)

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/Roflumilast_N-oxide.html

Purity

99.52

Solubility

DMSO : 250 mg/mL (ultrasonic)

Smiles

O=C(NC1=C(Cl)C=N(C=C1Cl)=O)C2=CC=C(OC(F)F)C(OCC3CC3)=C2

Molecular Formula

C17H14Cl2F2N2O4

Molecular Weight

419.21

Precautions

H302, H315, H320, H335

References & Citations

[1]Victoni T, et al. Roflumilast n-oxide associated with PGE2 prevents the neutrophil elastase-induced production of chemokines by epithelial cells. Int Immunopharmacol. 2016 Jan;30:1-8.|[2]Milara J, et al. Simvastatin Increases the Ability of Roflumilast N-oxide to Inhibit Cigarette Smoke-Induced Epithelial to Mesenchymal Transition in Well-differentiated Human Bronchial Epithelial Cells in vitro. COPD. 2015 Jun;12 (3) :320-31.|[3]Vollert S, et al. The glucose-lowering effects of the PDE4 inhibitors roflumilast and roflumilast-N-oxide in db/db mice. Diabetologia. 2012 Oct;55 (10) :2779-2788.